Literature DB >> 33562495

Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.

Seiji Mabuchi1, Tomoyuki Sasano2, Naoko Komura3.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity. They also directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In ovarian cancer, there are increased numbers of circulating or tumor-infiltrating MDSCs, and increased frequencies of MDSCs are associated with a poor prognosis or an advanced clinical stage. Moreover, in murine models of ovarian cancer, MDSC depletion has shown significant growth-inhibitory effects and enhanced the therapeutic efficacy of existing anticancer therapies. In this review, we summarize the current knowledge on MDSC biology, clinical significance of MDSC, and potential MDSC-targeting strategies in ovarian cancer.

Entities:  

Keywords:  MDSC; ovarian cancer; survival; therapeutic target; tumor microenvironment

Year:  2021        PMID: 33562495      PMCID: PMC7914407          DOI: 10.3390/cells10020329

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  70 in total

1.  Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.

Authors:  Naoki Horikawa; Kaoru Abiko; Noriomi Matsumura; Junzo Hamanishi; Tsukasa Baba; Ken Yamaguchi; Yumiko Yoshioka; Masafumi Koshiyama; Ikuo Konishi
Journal:  Clin Cancer Res       Date:  2016-07-11       Impact factor: 12.531

2.  Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Authors:  Isabel Poschke; Dimitrios Mougiakakos; Johan Hansson; Giuseppe V Masucci; Rolf Kiessling
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

3.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Authors:  Josephine Walton; Julianna Blagih; Darren Ennis; Elaine Leung; Suzanne Dowson; Malcolm Farquharson; Laura A Tookman; Clare Orange; Dimitris Athineos; Susan Mason; David Stevenson; Karen Blyth; Douglas Strathdee; Frances R Balkwill; Karen Vousden; Michelle Lockley; Iain A McNeish
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

4.  Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.

Authors:  Eiji Suzuki; Veena Kapoor; Arminder Singh Jassar; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

5.  Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.

Authors:  Kentaro Sumida; Daiko Wakita; Yoshinori Narita; Kazutaka Masuko; Satoshi Terada; Kazue Watanabe; Takayuki Satoh; Hidemitsu Kitamura; Takashi Nishimura
Journal:  Eur J Immunol       Date:  2012-08       Impact factor: 5.532

Review 6.  Myeloid-derived suppressor cell heterogeneity in human cancers.

Authors:  Samantha Solito; Ilaria Marigo; Laura Pinton; Vera Damuzzo; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Ann N Y Acad Sci       Date:  2014-06       Impact factor: 5.691

7.  Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

Authors:  Deanne M R Lathers; Joseph I Clark; Nicholas J Achille; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2003-11-26       Impact factor: 6.968

Review 8.  Antigen-specific active immunotherapy for ovarian cancer.

Authors:  Sterre T Paijens; Ninke Leffers; Toos Daemen; Wijnand Helfrich; H Marike Boezen; Ben J Cohlen; Cornelis Jm Melief; Marco de Bruyn; Hans W Nijman
Journal:  Cochrane Database Syst Rev       Date:  2018-09-10

9.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.

Authors:  Paolo Serafini; Kristen Meckel; Michael Kelso; Kimberly Noonan; Joseph Califano; Wayne Koch; Luigi Dolcetti; Vincenzo Bronte; Ivan Borrello
Journal:  J Exp Med       Date:  2006-11-13       Impact factor: 14.307

10.  Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.

Authors:  Thaïs Baert; Ann Vankerckhoven; Matteo Riva; Anaïs Van Hoylandt; Gitte Thirion; Gerhardt Holger; Thomas Mathivet; Ignace Vergote; An Coosemans
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

View more
  5 in total

1.  Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice.

Authors:  Dasha Fuentes; Alejandro Cabezas-Cruz; Circe Mesa; Tania Carmenate; Darel Martínez; Anet Valdés-Zayas; Enrique Montero; Rolando Pérez
Journal:  J Breast Cancer       Date:  2022-04-26       Impact factor: 2.922

Review 2.  Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract.

Authors:  Karolina Soroczynska; Lukasz Zareba; Magdalena Dlugolecka; Malgorzata Czystowska-Kuzmicz
Journal:  Cells       Date:  2022-04-28       Impact factor: 7.666

Review 3.  New Discovery of Myeloid-Derived Suppressor Cell's Tale on Viral Infection and COVID-19.

Authors:  Soo-Jeung Park; Da-Eun Nam; Hae Chang Seong; Young S Hahn
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

4.  Regulatory T Cells in Pancreatic Cancer: Of Mice and Men.

Authors:  Carmen Mota Reyes; Elke Demir; Kaan Çifcibaşı; Rouzanna Istvanffy; Helmut Friess; Ihsan Ekin Demir
Journal:  Cancers (Basel)       Date:  2022-09-21       Impact factor: 6.575

Review 5.  Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer.

Authors:  Aarushi Audhut Caro; Sofie Deschoemaeker; Lize Allonsius; An Coosemans; Damya Laoui
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.